"Metabolic Drug Shown Beneficial for All Kidney Function Levels, Say Studies"

Recent studies reveal that SGLT2 inhibitors can significantly reduce the risks of kidney disease progression and mortality, benefiting individuals with varying kidney function levels and diabetes.

• Two large-scale studies presented at the American Society of Nephrology Kidney Week revealed that SGLT2 inhibitors decreased chronic kidney disease progression among over 70,000 participants.
• Findings published in JAMA indicate that SGLT2 inhibitors effectively lowered hospitalization and death rates in patients with diabetes and those without, regardless of their glomerular filtration rate.
• The research highlights the significant impact of albuminuria in assessing kidney health, demonstrating that SGLT2 inhibitors can improve outcomes for all patients, not just those with type 2 diabetes.